HCP2102
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 05, 2024
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3 | N=249 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
August 02, 2022
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3 | N=246 | Recruiting | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Hypertension
July 11, 2022
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3 | N=246 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P3 trial • Cardiovascular • Hypertension
1 to 3
Of
3
Go to page
1